Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework

View at publisher Summarise with VIRAT
Authors: Sanket Chaudhari, Hemant Kumar Tatapudi, Durga Ganesh Jami, Kishore Raju Vatsavai, Saisneha Kandhagatla
Cited by: 0
References: 73

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Belinostat (PXD101), a hydroxamate-class histone deacetylase inhibitor (HDACi), was approved by the US FDA for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This review covers belinostat's pharmacological characteristics (including its mode of action), pharmacokinetics, toxicity, drug interactions, and analytical methods. Belinostat inhibits HDACs from Classes I and II, which then raises the acetylation of both histone and nonhistone proteins, resulting in growth cycle arrest and ultimately leading to the death of the malignant cells. The pharmacokinetics of belinostat include a brief elimination half-life and substantial first-pass metabolism in the liver, mostly via UGT1A1. Belinostat's efficacy has been proven in numerous clinical trials, which also revealed a certain level of cytotoxicity specific to tumor cells. Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.

Fields of Study & Subjects

Histone Deacetylase Inhibitors Research Analytical Methods in Pharmaceuticals Forensic Toxicology and Drug Analysis

Publication details

Journal / source
Biomedical Chromatography
Volume
40
Issue
5
Pages
e70424–e70424
Publication date
25 March 2026
Language
EN